Therapeutic HIV Peptide Vaccine

Area of Science:

• Immunology
• Vaccinology
• HIV Research

Background:

• Therapeutic vaccines are crucial for controlling chronic HIV infection and potentially achieving a functional cure, reducing reliance on lifelong antiretroviral therapy (ART).
• Current strategies focus on inducing new T cell immunity against conserved HIV epitopes, particularly in individuals with frequent HLA supertypes.

Purpose of the Study:

• To outline a protocol for a therapeutic HIV vaccine targeting subdominant conserved HIV-1 epitopes.
• To provide rationale for selecting specific HIV peptides and adjuvants to enhance immunogenicity and immune response direction.

Main Methods:

• Development of a peptide subunit vaccine approach using specific HIV-1 epitopes.
• Inclusion of adjuvants to improve the reduced immunogenicity often seen with peptide vaccines.
• Consideration of HLA supertype restriction for targeted T cell immunity.

Main Results:

• Peptide subunit vaccines offer safety advantages due to their simplicity, quality, purity, and low toxicity.
• Adjuvants are essential to enhance and direct the immune response, overcoming the inherent limitation of reduced immunogenicity in peptide vaccines.

Conclusions:

• The proposed therapeutic vaccine protocol shows promise for controlling chronic HIV infection.
• Recommend future testing in individuals on early ART to leverage improved immune function and identify those most likely to benefit from this HIV vaccine approach.